MISSISSIPPI DIVISION OF MEDICAID
Pharmacy & Therapeutics Committee
Woolfolk Building
Conference Center East, Room 145
Jackson, MS 39201-1399
August 13, 2019
9:00am to 5:00pm

AGENDA

I. Call to Order
II. Welcome & Introductions
III. Administrative Matters
IV. Approval of May 7, 2019 Meeting Minutes
V. PDL Compliance/Generic Percent Report Updates
VI. Drug Class Announcements
VII. Public Comment
VIII. New Drug/New Generic Reviews
   a. Analgesics, Narcotic, Short Acting-Apadaz (Benzhydrocodone/APAP)
   b. Anticonvulsants, Adjuvants- Diacomit (Stiripentol)
   c. Antineoplastics, Select Enzyme Inhibitors- Balversa (erdafitinib)
   d. Antiretrovirals, Single Tablet Regimens-Dovato (dolutegravir-lamivudine)
   e. Bone Resorption Suppression & Related Agents- Evenity (romosozumab-aqqg)
   f. Cytokine & CAM Antagonists- Skrizi (risankizumab-razaa)
   g. Immune Globulins
      1. Cablivi (caplacizumab-yhdp)
      2. Cutaquig (immune globulin- hipp)
   h. Multiple Sclerosis Agents, Oral
      1. Mavenclad (cladribine)
      2. Mayzent (siponimod)
   i. NSAIDS, COX II Selective- Qmiiz ODT (meloxicam) financial review
   j. Ophthalmic, Glaucoma Agents- Rocklatan (netarsudil-latanoprost)
   k. Steroids (Topical), Very High Potency
      1. Duobrii (halobetasol/tazarotene)
      2. Lexette (halobetasol propionate) financial review
   l. Tetracyclines- Seysara (sarecycline)
IX. Division of Medicaid Update
X. Next Meeting Date- Tuesday, October 22, 2019
XI. Adjournment